LSNE Completes FDA Inspection - - BioPharm International

ADVERTISEMENT

LSNE Completes FDA Inspection


Lyophilization Services of New England (LSNE), a New Hampshire based contract-manufacturing organization, has completed an FDA inspection of its Manchester manufacturing facility. This is the sixth successful inspection of the site, which is currently functioning as a multiproduct medical device manufacturing facility. The November 2013 inspection was a combination FDA general GMP and pre-approval inspection. The inspection resulted in no Form 483 being issued, as there were no observations noted by FDA.

This FDA inspection follows a successful UK Medicines and Healthcare Products Regulatory Agency (MHRA) inspection of the LSNE 25 Commerce Drive, Bedford NH contract pharmaceutical manufacturing facility in which LSNE received a certificate of GMP Compliance from the MHRA to manufacture aseptic lyophilized drug products for use in the EU.

Source: Lyophilization Services of New England

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here